Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

Yu Yuanyuan; Zhang Zicheng; Meng Qianhao; Wang Ke; Li Qingwei; Ma Yue; Yao Yuanfei; Sun Jie; Wang Guangyu

doi:10.5230/jgc.2022.22.e11

추천

검색

자료유형: 학술저널

저자정보: Yu Yuanyuan (Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Ch) Zhang Zicheng (School of Biomedical Engineering Wenzhou Medical University Wenzhou China.) Meng Qianhao (Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Ch) Wang Ke (Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Ch) Li Qingwei (Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Ch) Ma Yue (Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Ch) Yao Yuanfei (Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Ch) Sun Jie (School of Biomedical Engineering Wenzhou Medical University Wenzhou China.) Wang Guangyu (Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Ch)

저널정보: 대한위암학회 Journal of Gastric Cancer Journal of Gastric Cancer 제22권 제2호

발행연도: 2022.4

수록면: 107 - 119 (13page)

DOI: 10.5230/jgc.2022.22.e11

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: We aimed to explore whether the prognosis of patients treated with capecitabine and oxaliplatin (XELOX) or S-1 and oxaliplatin (SOX) regimens who received fewer cycles of chemotherapy after D2 radical resection for gastric cancer (GC) would be non-inferior to that of patients who received the standard number of cycles of chemotherapy. Materials and Methods: Data on patients who received XELOX or SOX chemotherapy after undergoing D2 radical resection at Harbin Medical University Cancer Hospital between January 2011 and May 2016 were collected. Results: In patients who received 4, 6, and 8 cycles of chemotherapy, the 5-year overall survival (OS) rates were 59.4%, 64.8%, and 62.7%, respectively. Compared to patients who received 4 cycles of chemotherapy, those who received 6 cycles (hazard ratio [HR], 0.882; 95% confidence interval [CI], 0.599?1.299; P=0.52) or 8 cycles (HR, 0.882; 95% CI, 0.533?1.458; P=0.62) of chemotherapy did not exhibit significantly prolonged OS. The 3-year disease-free survival (DFS) rate of patients who received 4, 6, and 8 cycles of chemotherapy was 62.1%, 67.2%, and 60.8%, respectively. Compared to patients who received 4 cycles of chemotherapy, those who received 6 cycles (HR, 0.835; 95% CI, 0.572?1.221; P=0.35) or 8 cycles (HR, 0.972; 95% CI, 0.606?1.558; P=0.91) of chemotherapy did not show significantly prolonged DFS. However, the 3-year DFS and 5-year OS rates of patients who received 6 cycles of chemotherapy appeared to be superior to those of patients who received 4 and 8 cycles of chemotherapy. Conclusions: For patients with stage III GC, 4 to 6 cycles of XELOX or SOX chemotherapy may be a favorable option. This study provides a rationale for further randomized clinical trials.

#Chemotherapy cycles #Adjuvant chemotherapy #Gastric cancer #Capecitabine #Oxaliplatin #S-1

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Yu Yuanyuan

소속기관 Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Ch